Chronic Cerebrovascular Diseases on the Background of Metabolic Syndrome: New Approaches to Treatment

Tanashyan, M. M.; Лагода, О.В.; Антонова, К.В.

doi:10.1007/s11055-014-9891-8

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…У пациентов с хроническими ЦВЗ отмечено улучшение или появление адекватной реакции в виде уменьшения АДФ-агрегации тромбоцитов и увеличения фибрино-литической активности крови после проведения биохимической манжеточной пробы, причем у пациентов с сопутствующим МС эти изменения более значимы (в том числе из-за выраженных базовых изменений). Аналогичная тенденция улучшения функции эндотелия отмечена и по результатам ультразвукового исследования эндотелийзависимой вазодилатации (ультразвуковая манжеточная проба), что также свидетельствует об улучшении атромбогенных свойств сосудистой стенки на фоне лечения мексидолом [30]. Исследование сосудодвигательной функции эндотелия при проведении ультразвуковой манжеточной пробы, которая у здоровых приводит к увеличению диа-метра плечевой артерии на 10% и более, у обследованных нами больных с МС выявило достоверное снижение функции эндотелия в виде изменения артерии лишь на 7% при хронических ЦВЗ и на 4% -у пациентов с острыми ЦВЗ.…”

Section: рис 1 атромбогенная активность эндотелия у пациентов с цвзunclassified

Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment

Tanashyan

Лагода

Антонова

2015

Z. nevrol. psikhiatr. im. S.S. Korsakova

Self Cite

View full text Add to dashboard Cite

Metabolic syndrome is a serious risk factor for acute and chronic cerebrovascular disease, which are a leading cause of disabling conditions. The association of proatherogenic effects of the main components of metabolic syndrome--hyperinsulinemia, arterial hypertension, dyslipidemia and obesity--leads to prominent haemorheological and hemostasis changes, which in turn play a pivotal role in the initiation, course and outcome of cerebrovascular pathology. Metabolic syndrome also influences the efficacy of the main pathogenetic therapy of cerebrovascular diseases--antithrombotic therapy. Thus, primary and secondary prevention of cerebrovascular disease in patients with metabolic syndrome should include haemangiocorrective, antithrombotic, antioxidant and endothelium-protective treatment, as well as therapy of the main components of metabolic syndrome.

show abstract

Section: рис 1 атромбогенная активность эндотелия у пациентов с цвзunclassified

Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment

Tanashyan

Лагода

Антонова

2015

Z. nevrol. psikhiatr. im. S.S. Korsakova

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is shown by the high efficacy of reperfusion therapy which includes a combination of systemic thrombolysis and mechanical thrombectomy using stent retrievers (Lee 2017, Skvortsova et al 2018. Vasoactive agents are widely used in neurological practice, such as mexidol (Tanashyan et al 2012, Voronina 2000, picamilon (Gusev et al 2018, Mirzoyan et al 2018) and a calcium channel blocker nimodipine (Nishizawa et al 2008, Scriabine andvan den Kerckhoff 1988), which possess significant cerebrovascular antiischemic activity (Mirzoyan et al 2018).…”

Section: Introductionmentioning

confidence: 99%

New cerebrovascular agent with hypotensive activity

Kim¹,

Ганьшина²,

Курза³

et al. 2019

RRP

View full text Add to dashboard Cite

Introduction: In cerebrovascular disorders, special attention is paid to a hypertensive cerebrovascular crisis, which combines a vascular injury of the brain and hypertension. The paper studies the cerebrovascular properties of the calcium channel blocker of S-Amlodipine nicotinate antihypertensive agent. Materials and methods: Tests were performed on 96 nonlinear male rats, measuring local blood flow in the cerebral cortex in 36 awake animals, using a laser Doppler flowmeter. Cerebral circulation was recorded in the animals when modeling ischemic and hemorrhagic brain injuries. Results and discussion: S-Amlodipine nicotinate (0.1 mg/kg i/v) shows a pronounced cerebrovascular activity in the models of ischemic and hemorrhagic injuries of the brain. In terms of the vasodilating effect in ischemic brain injury, the drug is comparable to mexidol, nimodipine, picamilon, but is superior to nimodipine and picamilon in terms of duration of action, and in the model of hemorrhagic stroke, S-Amlodipine nicotinate is superior to nimodipine and is comparable to picamilon and mexidol. The analysis of the mechanism of action of the agent revealed the participation of GABA A-receptors in the implementation of cerebrovascular properties of the agent. Conclusion: Significant cerebrovascular activity of S-Amlodipine nicotinate (0.1 mg/kg i/v) antihypertensive agent was revealed. The presence of GABAergic mechanism on cerebral blood flow in the agent action along with blockade of slow calcium channels ensures its high efficacy in treatment of both ischemic and hemorrhagic brain injuries.

show abstract

The efficacy of ethylmethylhydroxypyridine succinate in patients with cerebrovascular pathology complicated with diabetes mellitus and metabolic syndrome

Екушева

Biryukova

2020

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Chronic Cerebrovascular Diseases on the Background of Metabolic Syndrome: New Approaches to Treatment

Cited by 4 publications

References 4 publications

Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment

Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment

New cerebrovascular agent with hypotensive activity

The efficacy of ethylmethylhydroxypyridine succinate in patients with cerebrovascular pathology complicated with diabetes mellitus and metabolic syndrome

Contact Info

Product

Resources

About